View Item 

Show simple item record

Tegaserod for Female Patients Suffering From IBS With Mixed Bowel Habits or Constipation: A Randomized Controlled Trial
dc.contributor.authorChey, William D.en_US
dc.contributor.authorParé, Pierreen_US
dc.contributor.authorViegas, Andreaen_US
dc.contributor.authorLigozio, Gregoryen_US
dc.contributor.authorShetzline, Michael A.en_US
dc.date.accessioned2010-06-01T20:37:11Z
dc.date.available2010-06-01T20:37:11Z
dc.date.issued2008-05en_US
dc.identifier.citationChey, William D.; ParÉ, Pierre; Viegas, Andrea; Ligozio, Gregory; Shetzline, Michael A. (2008). "Tegaserod for Female Patients Suffering From IBS With Mixed Bowel Habits or Constipation: A Randomized Controlled Trial." The American Journal of Gastroenterology 103(5): 1217-1225. <http://hdl.handle.net/2027.42/73726>en_US
dc.identifier.issn0002-9270en_US
dc.identifier.issn1572-0241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73726
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18477346&dopt=citationen_US
dc.format.extent584766 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights© 2008 American College of Gastroenterology/Blackwell Publishing.en_US
dc.titleTegaserod for Female Patients Suffering From IBS With Mixed Bowel Habits or Constipation: A Randomized Controlled Trialen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan Health System, Division of Internal Medicine, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherUniversity Laval, Division of Gastroenterology, CHAUQ- HÔpital du St-Sacrement, Quebec City, Canadaen_US
dc.contributor.affiliationotherNovartis Pharmaceuticals Corporation, East Hanover, New Jerseyen_US
dc.identifier.pmid18477346en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73726/1/j.1572-0241.2008.01808.x.pdf
dc.identifier.doi10.1111/j.1572-0241.2008.01808.xen_US
dc.identifier.sourceThe American Journal of Gastroenterologyen_US
dc.identifier.citedreferenceDrossman DA, Morris CB, Hu Y, et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: Defining an alternator. Gastroenterology 2005; 128: 580 – 9.en_US
dc.identifier.citedreferenceThompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and D. functional abdominal pain. In: Drossman DA, Talley NJ, Thompson WG, et al., eds. Rome II: Functional gastrointestinal disorders: Diagnosis, pathophysiology, and treatment, 2nd Ed. McLean, VA: Degnon Associates, Inc., 2000: 351 – 432.en_US
dc.identifier.citedreferenceHungin AP, Whorwell PJ, Tack J, et al. The prevalence patterns and impact of irritable bowel syndrome: An international survey of 40,000 subjects. Aliment Pharmacol Ther 2003; 17: 643 – 50.en_US
dc.identifier.citedreferenceHungin APS, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: Prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005; 21: 1365 – 75.en_US
dc.identifier.citedreferenceMearin F, Balboa A, Badia X, et al. Irritable bowel syndrome subtypes according to bowel habit: Revisiting the alternating subtype. Eur J Gastroenterol Hepatol 2003; 15: 165 – 72.en_US
dc.identifier.citedreferenceTillisch K, Labus JS, Naliboff BD, et al. Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol 2005; 100: 896 – 904.en_US
dc.identifier.citedreferenceLongstreth G, Thompson WG, Chey WD, et al. Rome III: Functional bowel disorders. Gastroenterology 2006; 130: 1480 – 91.en_US
dc.identifier.citedreferenceCamilleri M, Prather CM. The irritable bowel syndrome: Mechanisms and a practical approach to management. Ann Intern Med 1992; 116: 1001 – 8.en_US
dc.identifier.citedreferenceKellow JE, Azpiroz F, Delvaux M, et al. Applied principles of neurogastroenterology: Physiology/motility sensation. Gastroenterology 2006; 130: 1412 – 20.en_US
dc.identifier.citedreferenceGershon M. Review article: Serotonin receptors and transporters—roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004; 20 ( Suppl 7 ): 3 – 14.en_US
dc.identifier.citedreferenceCrowell MD, Shetzline MA, Moses PL, et al. Enterochromaffin cells and 5-HT signaling in the pathophysiology of disorders of gastrointestinal function. Curr Opin Investig Drugs 2004; 5: 55 – 60.en_US
dc.identifier.citedreferenceCoates MD, Johnson AC, Greenwood-Van Meerveld B, et al. Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse. Neurogastroenterol Motil 2006; 18: 464 – 71.en_US
dc.identifier.citedreferenceNovick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877 – 88.en_US
dc.identifier.citedreferenceMuller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655 – 66.en_US
dc.identifier.citedreferenceMuller-Lissner S, Holtmann G, Rueegg P, et al. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2005; 21: 11 – 20.en_US
dc.identifier.citedreferenceKellow JE. Advances in the management of irritable bowel syndrome. J Gastroenterol Hepatol 2002; 17: 503 – 7.en_US
dc.identifier.citedreferenceCamilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 1149 – 59.en_US
dc.identifier.citedreferenceCamilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial. Lancet 2000; 355: 1035 – 40.en_US
dc.identifier.citedreferenceChey WD, Chey WY, Heath AT, et al. Long-term efficacy and safety of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004; 99: 2195 – 203.en_US
dc.identifier.citedreferenceBuchheit KH, Buhl T. Prokinetic benzamides stimulate peristaltic activity in the isolated guinea pig ileum by activation of 5-HT4 receptors. Eur J Pharmacol 1991; 205: 203 – 8.en_US
dc.identifier.citedreferencePrather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463 – 8.en_US
dc.identifier.citedreferenceDegen L, Matzinger D, Mertz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 1745 – 51.en_US
dc.identifier.citedreferenceThewissen M, Ruehl A, Enck P. On the adequate stimulus for rectal mechanoreception and perception: A study in cat and humans. Neurogastroenterol Motil 2000; 12: 43 – 52.en_US
dc.identifier.citedreferenceSchikowski A, Thewissen M, Mathis C, et al. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 2002; 14: 221 – 7.en_US
dc.identifier.citedreferenceCoffin B, Farmachidi JP, Rueegg P, et al. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003; 17: 577 – 85.en_US
dc.identifier.citedreferenceKellow J, Lee OY, Chang FY, et al. An Asia Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671 – 6.en_US
dc.identifier.citedreferenceTack J, Muller-Lissner S, Bytzer P, et al. A randomized controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation (IBS-C). Gut 2005; 54: 1707 – 13.en_US
dc.identifier.citedreferenceNyhlin H, Bang C, Elsborg L, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004; 39: 119 – 26.en_US
dc.identifier.citedreferenceO'Donnell LJD, Virjee J, Heaton KW. Detection of pseudodiarrhea by simple clinical assessment of intestinal transit rate. BMJ 1990; 300: 439 – 40.en_US
dc.identifier.citedreferencePan W. Sample size and power calculations with correlated binary data. Control Clin Trials 2001; 22: 211 – 7.en_US
dc.identifier.citedreferenceIrvine JE, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006; 130: 1538 – 51.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1572-0241.2008.01808.x.pdf
Size:
571.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.